CRS-100 is a bacteria-based immune therapy that targets liver metastases.
The primary objectives of the study are to determine the maximum tolerated dose and to explore the safety profile of a single dose of CRS-100 in adult patients with cancer that has metastasized to the liver.
CRS-100 is a proprietary attenuated strain of Listeria monocytogenes that has been designed by Cerus to increase safety margins while preserving its potential to trigger a powerful immune response.
The clinical trial is designed to explore safety and tolerability of CRS-100 in volunteer patients who have carcinoma, refractory to standard treatment and who additionally have liver metastases. The trial is currently being conducted at two centers in the US.
Liver metastases arise from a number of cancers, including colon and pancreas cancers. Despite recent advances, metastasized colorectal and pancreatic cancers remain significant unmet medical needs.